The Technical Analyst
Cingulate Inc. [CING]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cingulate Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.71% $0.880
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.50 mill |
| EPS: | -26.00 |
| P/E: | -0.0300 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 3.98 mill |
| Avg Daily Volume: | 0.317 mill |
| RATING 2024-04-26 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0300 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.737 - 1.023 ( +/- 16.25%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Werth Peter J. | Buy | 694 096 | Common Stock |
| 2024-04-11 | Werth Peter J. | Buy | 341 912 | Common Stock |
| 2024-04-11 | Werth Peter J. | Sell | 694 096 | Pre-Funded Warrant (right to buy) |
| 2024-04-11 | Werth Peter J. | Sell | 341 912 | Pre-Funded Warrant (right to buy) |
| 2024-03-29 | Silva Raul R. | Buy | 1 000 | Stock Option (right to Buy) |
| INSIDER POWER |
|---|
| 77.37 |
| Last 96 transactions |
| Buy: 11 671 641 | Sell: 1 062 040 |
Forecast:
16:00 - $0.880
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.880
Forecast 2: 16:00 - $0.880
Forecast 3: 16:00 - $0.880
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.880 (1.71% ) |
| Volume | 0.0086 mill |
| Avg. Vol. | 0.317 mill |
| % of Avg. Vol | 2.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CING
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $1.240 | N/A | Active |
|---|
CING
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Latest Press Releases
2024-04-16 17:00:00 - Press Release
Cingulate To Participate In Planet Microcap Showcase: Vegas 2024
Kansas city, kan., april 16, 2024 (globe newswire) -- cingulate inc. (nasdaq: cing), a biopharmaceutical company utilizing its proprietary precision timed release™ (ptr™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it will present at the planet microcap showcase: vegas 2024 conference on wednesday, may 1, 2024, at 2:30 pm pst. management will also host individual investor meetings on thursday, may 2.
2024-04-01 08:00:00 - Press Release
Cingulate Inc. Reports Fourth Quarter And Full Year 2023 Financial Results and Provides Clinical And Business Update
$17.8 million raised since beginning of 2023 $9.1 million of debt converted to equity at a premium phase 3 adhd data continues to impress
2024-03-19 16:45:00 - Press Release
Cingulate To Participate In Benzinga All Live Access Event
Kansas city, kan., march 19, 2024 (globe newswire) -- cingulate inc. (nasdaq: cing), a biopharmaceutical company utilizing its proprietary precision timed release™ (ptr™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that chairman and ceo shane j. schaffer will participate in a live benzinga all access event on friday march 22, 2024, at 12 p.m. et.
2024-03-06 06:45:00 - Press Release
Cingulate To Attend Dcat Week 2024 In New York City
Will host licensing meetings with multiple parties to discuss assets, pipeline and technology will host licensing meetings with multiple parties to discuss assets, pipeline and technology
2024-02-13 06:45:00 - Press Release
Cingulate Appoints Jay Roberts, Bryan Lawrence, And Jeff Ervin To Its Board Of Directors
Announcement follows recent public offering and successful capital raising activity announcement follows recent public offering and successful capital raising activity
Latest News
2023-12-28 10:15:02 - InvestorPlace
Why Is Cingulate (CING) Stock Up 160% Today?
Cingulate (NASDAQ: CING ) stock is soaring over 160% in early trading and trending on many financial news websites. The rally was sparked by the company's announcement that the Nasdaq exchange would postpone delisting its shares for several weeks.
2023-12-28 07:19:00 - Market Watch
Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing
Shares of Cingulate Inc. CING, +101.52% blasted 226.3% higher in premarket trading Thursday after the biopharmaceutical company disclosed that the delisting of its stock has been delayed until at least February. After closing Tuesday at a record low of $1.98, the stock had soared a record 101.5% on Wednesday.
2023-09-21 11:23:00 - Newsfile Corp
Cingulate Inc. To Present at the LD Micro Main Event XVI
Presentation on Wednesday, October 4th at 02:30 PM PT Kansas City, Kansas--(Newsfile Corp. - September 21, 2023) - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that Chairman & CEO, Shane J. Schaffer, will be presenting a company overview at the 16th annual Main Event on Wednesday, October 4th at 02:30 PM PT at the Luxe Sunset Boulevard Hotel.
2023-06-14 15:45:00 - GlobeNewsWire
Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, Pharm D, has been invited to participate in the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest. The three-day conference will kick off Tuesday, June 20th at 9:00 AM EST, and conclude on Thursday, June 22nd.
2023-05-25 15:55:00 - GlobeNewsWire
Cingulate to Present at 13th Annual LD Micro Invitational
KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it will participate in the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Los Angeles, California, on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private one-on-one meetings.
2023-03-10 13:20:19 - PennyStocks
Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch
2023-02-27 06:00:00 - PennyStocks
Building a Penny Stocks Portfolio For Long Term
Use these tips for buying penny stocks for the long term The post Building a Penny Stocks Portfolio For Long Term appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-02-25 11:00:00 - PennyStocks
The Psychology of Penny Stock Trading: Tips for Emotional Control
Tips for making money with penny stocks The post The Psychology of Penny Stock Trading: Tips for Emotional Control appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-02-24 07:47:45 - InvestorPlace
Why Is Cingulate (CING) Stock Up 72% Today?
Cingulate (NASDAQ: CING ) stock is on the rise Friday after releasing positive data concerning its ADHD treatment. The big news today is Cingulate's CTx-1301 can be taken with or without food.
2023-02-24 07:04:00 - Market Watch
Cingulate stock skyrockets after ADHD treatment shows positive trial results
Shares of Cingulate Inc. CING, +2.78% skyrocketed 82.9% toward an 11-month high in active premarket trading Friday, after the biopharmaceutical company reported positive results from a trial of its attention deficit/hyperactivity disorder (ADHD) treatment. With trading volume spiking to over 3.2 million shares, compared with the full-day average of about 112,400 shares, the stock was the biggest gainer and most active listed on major U.S. exchanges.